RT Journal Article
SR Electronic
T1 Tocilizumab in Giant Cell Arteritis: A Multicentre Retrospective Study of 34 Patients
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.151252
DO 10.3899/jrheum.151252
A1 Alexis Régent
A1 Serge Redeker
A1 Alban Deroux
A1 Pierre Kieffer
A1 Kim Heang  Ly
A1 Maxime Dougados
A1 Eric Liozon
A1 Claire Larroche
A1 Loïc Guillevin
A1 Laurence Bouillet
A1 Olivier Espitia
A1 Nathalie Costedoat-Chalumeau
A1 Martin Soubrier
A1 Benoît Brihaye
A1 François Lifermann
A1 Guillaume Lefevre
A1 Xavier Puéchal
A1 Luc Mouthon
A1 Eric Toussirot
YR 2016
UL http://www.jrheum.org/content/early/2016/05/10/jrheum.151252.abstract
AB Objective To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA). Methods A retrospective multicenter study that included 34 patients receiving TCZ for GCA. Results TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months. Conclusion TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.